Phio Pharmaceuticals Corp. (PHIO) is a biotechnology company in Massachusetts, United States, which is committed to developing treatments for cancer and other severe diseases. PHIO specializes in utilizing its robust RNAi technology platform for the discovery and development of next-generation therapeutics.
Established in 2007, Phio Pharmaceutical Corp. is publically traded on the Nasdaq stock exchange. The company stands out in the industry due to its impressive technological platform which employs the RNA interference (RNAi) technique, recognized as a revolutionary method in the field of gene silencing. This sophisticated technology targets and silences specific genes responsible for the progression of diseases, including cancer, ultimately helping to control their spread.
The RNAi technique has been applauded globally for its potential, earning the 2006 Nobel Prize in Physiology or Medicine. Phio Pharmaceutical's use of this technique provides an innovative approach to drug development, which may bring drastic improvements in patient outcomes and quality of life.
One of the inspiring missions of Phio Pharmaceuticals is to make impossible-to-treat tumors possible to treat. To fulfill this, Phio is dedicated to working tirelessly to advance the science of RNAi. Several promising product candidates and preclinical studies are underway at the company, such as PH-762, PH-790, and PH-804. Each of these are designed to augment immune responses in the body against cancer cells by silencing the genes that prevent the immune system from destroying the tumors.
Two major components of this company’s corporate strategy include driving the development of novel RNAi technologies and compounds to commercial viability and establishing strategic collaborations to facilitate rapid and effective commercialization worldwide. Such collaborations help leverage the company’s technological expertise and expand their impact on global healthcare.
The leadership team at Phio Pharmaceuticals includes pioneers and influential figures in biotechnology and pharmaceuticals, led by Dr. Gerrit Dispersyn, the company's President and CEO. Together, they strive to guide the company towards achieving its mission and making significant strides in RNAi technology development.
In conclusion, Phio Pharmaceuticals Corp. (PHIO) is not merely a player in the biotechnology and pharmaceuticals sector but a game-changer. Their ongoing research and commitment to utilizing RNAi technology for the development of transformative therapeutics posit them as an influential force driving the evolution of cancer treatment. It is evident that with continued success, Phio Pharmaceuticals could herald a new era of healthcare by delivery groundbreaking drugs to patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Phio Pharmaceuticals director Patricia A. Bradford recently acquired 12,000 shares of the company's stock at $1.03 per share on September 15, 2026. This transaction increased her total holdings to 57,651 shares, representing approximately 20.8% of her post-purchase stake. The acquisition, indicated by transaction code P, highlights a significant insider investment in Phio Pharmaceuticals (NASDAQ: PHIO).
Phio Pharmaceuticals (PHIO) Chairman Robert Bitterman has purchased an additional 10,000 shares of the company, bringing his total holdings to 431,421 shares. This transaction at $1.06 per share reflects a strong insider sentiment, with 6 insider buys and 0 insider sells over the past year, indicating confidence in the clinical-stage biotechnology company's future despite its micro-cap status and current lack of profitability. The article highlights that such insider activity, coupled with some guru ownership, suggests a belief that the stock's current valuation does not fully reflect its long-term potential, though investors should acknowledge the inherent risks of clinical-stage biotech.